Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache, S; Barton, F B; Moore, R D; Terrin, M L; Steinberg, M H; Dover, G J; Ballas, S K; McMahon, R P; Castro, O; Orringer, E P

Charache, S; Barton, F B; Moore, R D; Terrin, M L; Steinberg, M H; Dover, G J; Ballas, S K; McMahon, R P; Castro, O; Orringer, E P.

Affiliation

Charache S; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Medicine (Baltimore) ; 75(6): 300-26, 1996 Nov.

Article in En | MEDLINE | ID: mdl-8982148

Subject(s)

Anemia, Sickle Cell/drug therapy; Antisickling Agents/therapeutic use; Hydroxyurea/therapeutic use; Adolescent; Adult; Anemia, Sickle Cell/blood; Anemia, Sickle Cell/physiopathology; Antisickling Agents/adverse effects; Blood Cell Count; Double-Blind Method; Erythrocyte Indices; Female; Fetal Hemoglobin/analysis; Globins/genetics; Humans; Hydroxyurea/adverse effects; Male; Middle Aged

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Hydroxyurea / Anemia, Sickle Cell / Antisickling Agents Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Medicine (Baltimore) Year: 1996 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links